ARROWHEAD PHARMACEUTICALS IN (ARWR) Stock Price, Quote, News and Overview
NASDAQ:ARWR - Nasdaq - US04280A1007 - Common Stock - Currency: USD
ARWR Quote, Performance and Key Statistics
19.9
-1.06 (-5.06%)
The current stock price of ARWR is 19.9 USD. In the past month the price decreased by -7.57%. In the past year, price decreased by -37.02%.
ARWR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ARWR
Company Profile
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 525 full-time employees. The firm's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The firm's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. The company is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. The company has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The firm's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.
Company Info
ARROWHEAD PHARMACEUTICALS IN
177 E Colorado Blvd, Suite 700
Pasadena CALIFORNIA 91105 US
CEO: Christopher Anzalone
Employees: 525
Company Website: https://arrowheadpharma.com/
Investor Relations: https://ir.arrowheadpharma.com/
Phone: 16266964702
ARROWHEAD PHARMACEUTICALS IN / ARWR FAQ
What is the stock price of ARROWHEAD PHARMACEUTICALS IN today?
The current stock price of ARWR is 19.9 USD. The price decreased by -5.06% in the last trading session.
What is the ticker symbol for ARROWHEAD PHARMACEUTICALS IN stock?
The exchange symbol of ARROWHEAD PHARMACEUTICALS IN is ARWR and it is listed on the Nasdaq exchange.
On which exchange is ARWR stock listed?
ARWR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ARROWHEAD PHARMACEUTICALS IN stock?
21 analysts have analysed ARWR and the average price target is 46.7 USD. This implies a price increase of 134.68% is expected in the next year compared to the current price of 19.9. Check the ARROWHEAD PHARMACEUTICALS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ARROWHEAD PHARMACEUTICALS IN worth?
ARROWHEAD PHARMACEUTICALS IN (ARWR) has a market capitalization of 2.51B USD. This makes ARWR a Mid Cap stock.
How many employees does ARROWHEAD PHARMACEUTICALS IN have?
ARROWHEAD PHARMACEUTICALS IN (ARWR) currently has 525 employees.
What are the support and resistance levels for ARROWHEAD PHARMACEUTICALS IN (ARWR) stock?
ARROWHEAD PHARMACEUTICALS IN (ARWR) has a support level at 18.74 and a resistance level at 19.91. Check the full technical report for a detailed analysis of ARWR support and resistance levels.
Is ARROWHEAD PHARMACEUTICALS IN (ARWR) expected to grow?
The Revenue of ARROWHEAD PHARMACEUTICALS IN (ARWR) is expected to grow by 108.16% in the next year. Check the estimates tab for more information on the ARWR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ARROWHEAD PHARMACEUTICALS IN (ARWR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ARWR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ARWR, evaluating the profitability, health, valuation and growth aspects
- ARROWHEAD PHARMACEUTICALS IN (ARWR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ARROWHEAD PHARMACEUTICALS IN (ARWR) Sales and EPS estimates to see what analysts future expectations are.
- ARROWHEAD PHARMACEUTICALS IN (ARWR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ARROWHEAD PHARMACEUTICALS IN (ARWR) Insider and Institutional Ownership to learn about the owners and their transactions.
- ARROWHEAD PHARMACEUTICALS IN (ARWR) Stock Chart to make your own analysis
- ARROWHEAD PHARMACEUTICALS IN (ARWR) Latest news and press-releases to stay up to date.
Does ARROWHEAD PHARMACEUTICALS IN (ARWR) stock pay dividends?
ARWR does not pay a dividend.
When does ARROWHEAD PHARMACEUTICALS IN (ARWR) report earnings?
ARROWHEAD PHARMACEUTICALS IN (ARWR) will report earnings on 2025-05-07, after the market close.
What is the Price/Earnings (PE) ratio of ARROWHEAD PHARMACEUTICALS IN (ARWR)?
ARROWHEAD PHARMACEUTICALS IN (ARWR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.16).
What is the Short Interest ratio of ARROWHEAD PHARMACEUTICALS IN (ARWR) stock?
The outstanding short interest for ARROWHEAD PHARMACEUTICALS IN (ARWR) is 8.37% of its float. Check the ownership tab for more information on the ARWR short interest.
ARWR Technical Analysis
ARWR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ARWR. Both the profitability and financial health of ARWR have multiple concerns.
ARWR Financial Highlights
Over the last trailing twelve months ARWR reported a non-GAAP Earnings per Share(EPS) of -5.16. The EPS decreased by -86.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.11% | ||
| ROE | -1216.44% | ||
| Debt/Equity | 7.75 |
ARWR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to ARWR. The Buy consensus is the average rating of analysts ratings from 21 analysts.
For the next year, analysts expect an EPS growth of 24.15% and a revenue growth 108.16% for ARWR